vs
Side-by-side financial comparison of AUBURN NATIONAL BANCORPORATION, INC (AUBN) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
Spero Therapeutics, Inc. is the larger business by last-quarter revenue ($12.6M vs $8.5M, roughly 1.5× AUBURN NATIONAL BANCORPORATION, INC). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs 19.7%, a 231.0% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs 8.4%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs 5.9%).
Auburn Bank is an American community bank providing services in the East of Alabama as a state registered bank. The Bank offers financial products and services including checking, savings, and lending. The bank is a member of the Federal Home Loan Bank of Atlanta. Its operation is regulated by the Alabama Superintendent of Banks.
AUBN vs SPRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.5M | $12.6M |
| Net Profit | $1.7M | $31.5M |
| Gross Margin | — | — |
| Operating Margin | 25.1% | — |
| Net Margin | 19.7% | 250.7% |
| Revenue YoY | 8.4% | 24080.8% |
| Net Profit YoY | 6.7% | 250.9% |
| EPS (diluted) | — | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.5M | $12.6M | ||
| Q3 25 | $8.4M | $0 | ||
| Q2 25 | $8.1M | $0 | ||
| Q1 25 | $7.8M | $12.0K | ||
| Q4 24 | $7.8M | $52.0K | ||
| Q3 24 | $7.6M | $65.0K | ||
| Q2 24 | $7.6M | $114.0K | ||
| Q1 24 | $7.5M | $140.0K |
| Q4 25 | $1.7M | $31.5M | ||
| Q3 25 | $2.2M | $-7.4M | ||
| Q2 25 | $1.8M | $-1.7M | ||
| Q1 25 | $1.5M | $-13.9M | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $1.7M | $-17.1M | ||
| Q2 24 | $1.7M | $-17.9M | ||
| Q1 24 | $1.4M | $-12.7M |
| Q4 25 | 25.1% | — | ||
| Q3 25 | 33.9% | — | ||
| Q2 25 | 28.5% | — | ||
| Q1 25 | 24.7% | -122758.3% | ||
| Q4 24 | 30.6% | — | ||
| Q3 24 | 29.6% | -28604.6% | ||
| Q2 24 | 29.0% | -16720.2% | ||
| Q1 24 | 20.3% | -9987.1% |
| Q4 25 | 19.7% | 250.7% | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | 22.5% | — | ||
| Q1 25 | 19.6% | -115550.0% | ||
| Q4 24 | 20.0% | — | ||
| Q3 24 | 22.7% | -26380.0% | ||
| Q2 24 | 22.8% | -15668.4% | ||
| Q1 24 | 18.2% | -9049.3% |
| Q4 25 | — | $0.56 | ||
| Q3 25 | $0.64 | $-0.13 | ||
| Q2 25 | — | $-0.03 | ||
| Q1 25 | — | $-0.25 | ||
| Q4 24 | — | — | ||
| Q3 24 | $0.50 | $-0.32 | ||
| Q2 24 | — | $-0.33 | ||
| Q1 24 | — | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $40.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $92.1M | $59.0M |
| Total Assets | $1.0B | $68.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.3M | ||
| Q3 25 | — | $48.6M | ||
| Q2 25 | — | $31.2M | ||
| Q1 25 | — | $48.9M | ||
| Q4 24 | — | $52.9M | ||
| Q3 24 | — | $76.3M | ||
| Q2 24 | — | $63.5M | ||
| Q1 24 | — | $82.3M |
| Q4 25 | $92.1M | $59.0M | ||
| Q3 25 | $89.6M | $26.5M | ||
| Q2 25 | $86.1M | $32.8M | ||
| Q1 25 | $83.1M | $33.8M | ||
| Q4 24 | $78.3M | $46.1M | ||
| Q3 24 | $84.3M | $65.5M | ||
| Q2 24 | $75.2M | $80.5M | ||
| Q1 24 | $74.5M | $96.2M |
| Q4 25 | $1.0B | $68.9M | ||
| Q3 25 | $1.0B | $54.2M | ||
| Q2 25 | $1.0B | $62.1M | ||
| Q1 25 | $996.8M | $77.7M | ||
| Q4 24 | $977.3M | $110.5M | ||
| Q3 24 | $990.1M | $135.2M | ||
| Q2 24 | $1.0B | $149.9M | ||
| Q1 24 | $979.0M | $167.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $12.3M | $-8.4M |
| Free Cash FlowOCF − Capex | $10.9M | — |
| FCF MarginFCF / Revenue | 128.3% | — |
| Capex IntensityCapex / Revenue | 17.5% | — |
| Cash ConversionOCF / Net Profit | 7.42× | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $12.3M | $-8.4M | ||
| Q3 25 | $4.1M | $17.4M | ||
| Q2 25 | $2.1M | $-17.7M | ||
| Q1 25 | $2.6M | $-4.0M | ||
| Q4 24 | $10.8M | $-23.4M | ||
| Q3 24 | $1.9M | $12.8M | ||
| Q2 24 | $3.1M | $-18.7M | ||
| Q1 24 | $3.1M | $5.9M |
| Q4 25 | $10.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $8.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 128.3% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 111.6% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 17.5% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 26.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 7.42× | -0.26× | ||
| Q3 25 | 1.83× | — | ||
| Q2 25 | 1.17× | — | ||
| Q1 25 | 1.72× | — | ||
| Q4 24 | 6.93× | — | ||
| Q3 24 | 1.08× | — | ||
| Q2 24 | 1.76× | — | ||
| Q1 24 | 2.25× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
